The impact and mechanism of different doses of yangxinshi on cardiac angiogenesis of acute myocardial infarction in rats / 中国药学杂志

ABSTRACT

OBJECTIVE: To investigate the influence and mechanism of different doses of Yangxinshi on infarction region angiogenesis of Wistar rats after acute myocardial infarction. METHODS: Sixty healthy male Wistar rats were randomly divided into five groups, named as follow group A rosuvastatin group (0.75 mg·kg-1 ·d-1), group B high-dose Yangxinshi(0.27 g·kg-1 ·d-1), group C mid-dose Yangxinshi group (0.18 g·kg-1 ·d-1), group D Low-dose Yangxinshi group (0.09 g·kg-1 ·d-1), group E saline control group. A, B, C, D group was respectively given the drug by gavage, group E received normal saline by gavage. The models of acute myocardial infarction can be established in the forth week. After continued drugs for 4 weeks, rats were killed before detected blood biochemicalindexes such as blood lipids, liver and kidney function. Myocardial tissue was sliced and stained infarcted myocardium by HE to observe the pathological changes, also extract ischemic and infarct myocardium tissue protein and test VEGF protein expression with immunohistochemistry. RESULTS: Myocardial tissue HE staining were observed a lot of survival island cardiomyocytes and neonatal thin-walled capillaries in four treatment groups, however, control group exist less normal cardiomyocytes and capillaries mainly disappear. Immunohistochemistry results showed high-doses of Yangxinshi group express higher VEGF protein compared with mid-dose group, low-dose group and control group, the difference was statistically significant (P < 0.05), VEGF protein expression was significantly increased the in mid-dose and high-dose Yangxinshi groups than rosuvastatin group, the difference was statistically significant (P < 0.05). CONCLUSION: Yangxinshi promote production of VEGF protein and angiogenesis of ischemic myocardium, in addition its role and its dose is positive correlated. VEGF protein expression was significantly increased the in mid-dose and high-dose Yangxinshi groups than rosuvastatin group, the difference is statistically significant (P < 0.05).